Prostate cancer is the most common non-skin cancer in American men, with more than 60 percent of new diagnoses occurring in men 65 and older—the heart of the Medicare population. The treatment journey can span years and involve multiple Medicare benefit categories: Part B for physician services, outpatient procedures, and injected drugs; Part A for inpatient stays; and Part D for oral medications. Understanding which bucket pays for what determines how much you owe and whether a Medigap supplement or Medicare Advantage plan will leave you better or worse off financially.

This guide walks through every step of the prostate cancer experience under Medicare, from the first PSA blood test through active surveillance, surgery, radiation, hormone therapy, and advanced disease.

PSA Screening: Not a Free Preventive Service

Here is the first surprise for many Medicare beneficiaries: the prostate-specific antigen (PSA) blood test does not get Medicare’s “free preventive service” treatment the way a mammogram or colonoscopy does.

Medicare does cover a digital rectal examination (DRE) and PSA test once every 12 months for all male Medicare beneficiaries age 50 and older. However, unlike colonoscopies, which are billed under a special preventive code that waives the Part B deductible, the PSA is covered as a clinical diagnostic laboratory test under a separate payment system. The practical effect:

  • The PSA itself is paid at 100 percent by Medicare (no coinsurance, no deductible) because clinical laboratory tests are exempt from cost-sharing under Part B.
  • The DRE performed at the same visit, however, is billed as a physician office visit under Part B—meaning it is subject to the $257 Part B deductible (2026) and 20 percent coinsurance after that.
  • If the DRE and PSA are the only reason you came in, many urologists bundle the visit into a preventive visit code; how it is billed varies.

The net result: many men with Medigap Plan G pay nothing for their annual PSA because the lab fee is zero coinsurance and the visit deductible has usually been met. On Medicare Advantage, your in-network copay for the physician office visit applies.

Prostate Biopsy: Part B (Outpatient)

If PSA rises or a DRE finds a nodule, the next step is typically a transrectal ultrasound (TRUS)-guided biopsy or increasingly a fusion MRI-ultrasound biopsy. Both are covered under Part B as outpatient procedures:

  • Prostate MRI (multiparametric, or mpMRI): Covered under Part B for staging or guidance before a biopsy. You pay 20 percent of the approved amount after the deductible.
  • TRUS biopsy: Covered under Part B. Typically done in the urologist’s office or an outpatient facility. Cost-sharing is 20 percent of the Medicare-approved amount.
  • Fusion biopsy (MRI/TRUS): Also covered under Part B. The technology premium is generally absorbed into the professional fee.
  • Pathology/lab fees: Covered as clinical laboratory fees—zero cost-sharing for the pathology lab interpreting the biopsy cores.

If the biopsy requires anesthesia or is done in a hospital outpatient department (HOPD), the facility fee is subject to Part B 20 percent coinsurance. Total out-of-pocket for a biopsy in a HOPD without supplemental coverage can reach several hundred dollars.

Medigap Plan G: Covers the 20 percent coinsurance on all Part B services, meaning your only exposure is the $257 annual deductible.

Active Surveillance: Covered Monitoring

For low-risk prostate cancer (Gleason 6, PSA < 10), active surveillance—periodic PSA tests, MRIs, and repeat biopsies rather than immediate treatment—is guideline-endorsed. All the monitoring components are covered under Medicare:

  • PSA every 3–6 months: Part B lab coverage, zero coinsurance
  • Annual prostate MRI: Part B, 20 percent coinsurance
  • Surveillance biopsy: Part B, 20 percent coinsurance

The biggest financial risk with active surveillance is that it involves many office visits over years, with 20 percent coinsurance accumulating. For men with a Medigap supplement, this makes active surveillance essentially free beyond the deductible.

Robotic Prostatectomy: Part A or Part B?

Radical prostatectomy—surgical removal of the prostate—is now performed almost exclusively using the da Vinci robotic-assisted laparoscopic technique. The coverage classification depends entirely on where the surgery is performed and whether it meets the 2-midnight rule for inpatient admission.

Inpatient (Part A)

If the surgeon and hospital believe the procedure requires a medically necessary overnight stay of two or more midnights, the hospital admission is billed under Part A:

  • Part A hospital deductible: $1,676 per benefit period in 2026
  • Days 1–60: Deductible only, no daily coinsurance
  • The surgeon’s professional fee is billed separately under Part B (20 percent coinsurance)

Outpatient (Part B)

If the prostatectomy is classified as outpatient—increasingly common as recovery times shorten—the hospital facility fee is billed under Part B, not Part A:

  • Hospital outpatient facility fee: 20 percent coinsurance after the Part B deductible
  • Surgeon’s professional fee: Separate Part B claim, 20 percent coinsurance

This classification matters enormously because an outpatient surgical classification means your hospitalization does not count as a qualifying three-day inpatient stay for skilled nursing facility (SNF) coverage under Part A—relevant if complications require post-acute care.

Total out-of-pocket without supplemental coverage: The combination of facility fees, surgeon fees, anesthesia, and pathology for a robotic prostatectomy can easily reach $2,000–$5,000 in uncovered 20 percent coinsurance under original Medicare alone.

Medigap Plan G: Covers all Part B coinsurance (and the Part A deductible on inpatient admissions), capping most prostatectomy costs at the $257 Part B deductible.

Medicare Advantage: Prior authorization is typically required. Network restrictions matter significantly—confirm that your robotic surgeon is in-network before scheduling.

Radiation Therapy Options

Radiation is the primary alternative to surgery for localized prostate cancer and is also used post-prostatectomy for salvage treatment. All forms are covered under Part B as outpatient services, subject to 20 percent coinsurance.

External Beam Radiation Therapy (EBRT)

Conventional EBRT and modern techniques are all covered:

  • 3D-Conformal RT (3D-CRT): Standard; lower per-session cost but typically 42–45 daily fractions
  • Intensity-Modulated Radiation Therapy (IMRT): The current standard of care; premium reimbursement rate from Medicare. Typically 40–45 fractions, though hypofractionated regimens (20–28 fractions) are increasingly common
  • Stereotactic Body Radiation Therapy (SBRT): Also called CyberKnife or Accuray SBRT. 5 fractions total. Medicare covers SBRT under HOPD payment codes. The fewer fractions reduce total cost-sharing compared to conventional IMRT

For all EBRT forms, each fraction is a separate Part B claim with a separate facility fee (HOPD) and physician fee. Without supplemental coverage, a 40-fraction IMRT course can generate $4,000–$8,000 in 20 percent coinsurance charges.

Brachytherapy (Seed Implants)

Low-dose rate (LDR) brachytherapy (permanent radioactive seed implants, typically iodine-125 or palladium-103) is covered under Part B. It is usually done as an outpatient procedure under general or spinal anesthesia:

  • Procedure code + facility fee: 20 percent coinsurance
  • Radiation oncologist professional fee: 20 percent coinsurance
  • Dosimetry planning: Separate Part B payment

High-dose rate (HDR) brachytherapy, used in combination with EBRT for intermediate/high-risk disease, is similarly covered under Part B.

Proton Therapy

Medicare covers proton beam therapy for prostate cancer. Proton therapy is reimbursed at a higher rate than IMRT, and the total cost to Medicare is substantial. Your 20 percent coinsurance obligation—without a supplement—can reach $20,000–$30,000 for a full proton course. If you are considering proton therapy and do not have supplemental coverage, the financial exposure is severe. Plan G eliminates this coinsurance entirely.

Hormone Therapy (ADT): Part B vs. Part D

Androgen deprivation therapy (ADT) is the cornerstone of treatment for advanced and metastatic prostate cancer. How Medicare pays for ADT depends entirely on whether the drug is injected in a clinical setting (Part B) or self-administered by the patient (Part D).

Part B Injectable ADT

LHRH/GnRH agonists administered by a healthcare professional are covered under Part B as physician-administered drugs:

  • Leuprolide acetate (Lupron, Eligard): The most widely used ADT agent in the US. Medicare Part B covers depot injections (1-month, 3-month, 4-month, and 6-month formulations) given in the physician’s office. You pay 20 percent of the Medicare-approved amount for both the drug and the injection administration.

    Cost example: A 3-month Lupron depot injection has a Medicare-approved amount of approximately $1,200–$1,600 per administration. Without supplemental coverage, your 20 percent coinsurance is $240–$320 every 3 months, or roughly $960–$1,280 per year.

  • Goserelin acetate (Zoladex): Monthly or 3-month implant injected subcutaneously in the physician’s office. Part B coverage, 20 percent coinsurance.

  • GnRH antagonists — Degarelix (Firmagon): Monthly subcutaneous injection in the physician’s office. Part B coverage. Degarelix is preferred when rapid testosterone suppression is needed (e.g., cord compression) because it avoids the testosterone flare seen with LHRH agonists.

  • Relugolix (Orgovyx): The new oral GnRH antagonist approved by FDA in 2020. Because it is a self-administered oral pill, it falls under Part D, not Part B. This matters significantly for cost-sharing.

Part D Oral ADT and Novel Hormonal Agents

Several advanced prostate cancer drugs are oral, self-administered, and covered under Part D:

  • Relugolix (Orgovyx): $1,800–$2,200/month retail. The $2,000 out-of-pocket cap under the redesigned Part D (2025–2026) means patients who qualify for Extra Help pay $0–$11/month, and other patients are capped at $2,000/year total out-of-pocket after reaching catastrophic coverage.

  • Enzalutamide (Xtandi): A second-generation androgen receptor inhibitor used for castration-sensitive and castration-resistant prostate cancer. Retail price approximately $11,000–$13,000/month. Part D coverage. The $2,000 out-of-pocket cap is transformative for patients on this drug—without the cap (pre-2025), catastrophic coinsurance of 5 percent on $12,000/month meant $600/month indefinitely. The cap now limits total exposure to $2,000/year.

  • Apalutamide (Erleada) and darolutamide (Nubeqa): Similar androgen receptor inhibitors, also oral, Part D coverage, similarly high retail prices with the same $2,000 cap protection.

  • Abiraterone acetate (Zytiga, generic): An androgen biosynthesis inhibitor (CYP17 inhibitor) used with prednisone. Generic abiraterone became available in 2022, dramatically reducing Part D costs. Generic price approximately $300–$800/month at specialty pharmacies, with standard Part D tiers applying.

  • Docetaxel (oral formulation): Not currently available orally; IV docetaxel is a Part B infusion drug.

Extra Help (Low-Income Subsidy)

For Part D oral ADT drugs costing thousands per month, the Low-Income Subsidy (Extra Help) program is the most important financial tool available. Eligible beneficiaries pay $0–$11.20/month for covered drugs regardless of retail price. The income threshold is 150 percent of the federal poverty level. See our guide to Medicare Savings Programs for eligibility details.

Advanced and Metastatic Prostate Cancer: Part B Infusion Drugs

For castration-resistant metastatic prostate cancer (mCRPC), several chemotherapy and targeted agents are covered as Part B infusion drugs administered in a clinical setting:

  • Docetaxel (Taxotere, generic): IV chemotherapy for mCRPC. Part B drug, administered in an outpatient oncology clinic. You pay 20 percent of the drug cost plus the infusion administration fee. Docetaxel cycles can cost $2,000–$5,000 in Medicare-approved charges; without Medigap, your 20 percent coinsurance per cycle accumulates rapidly.

  • Cabazitaxel (Jevtana): Second-line IV chemotherapy for mCRPC post-docetaxel. Part B drug. Higher drug cost than docetaxel, with proportionally higher 20 percent coinsurance.

  • Radium-223 (Xofigo): A radiopharmaceutical for mCRPC with bone metastases. Administered IV in an outpatient setting. Part B drug. Six injections over 6 months; the Medicare-approved amount per injection is approximately $8,000–$12,000, meaning 20 percent coinsurance of $1,600–$2,400 per injection without supplemental coverage.

  • Sipuleucel-T (Provenge): An FDA-approved immunotherapy vaccine for mCRPC. Three infusions, each approximately $35,000 in Medicare-approved charges. At 20 percent coinsurance, a patient without Medigap faces $7,000 per infusion, or $21,000 total for the three-infusion course.

  • Pembrolizumab (Keytruda): For the subset of mCRPC cases with mismatch repair deficiency (dMMR/MSI-H). Part B infusion drug. 20 percent coinsurance applies on the approximately $8,000–$12,000 per-infusion Medicare-approved amount.

Why Medigap Plan G is critical for cancer patients: The absence of an out-of-pocket maximum under original Medicare means a patient receiving multiple Part B drugs—Radium-223 plus docetaxel, for example—faces unl imited 20 percent coinsurance with no annual cap. Plan G eliminates all of this coinsurance (beyond the $257 Part B deductible). For anyone at risk of advanced prostate cancer, the value of Plan G far exceeds its premium cost. See Medigap Plans Compared for a full analysis.

Medicare Advantage: MA plans have a mandatory out-of-pocket maximum (up to $8,850 in-network in 2026), which does provide an annual cap. However, MA plans require prior authorization for infusion drugs and may use restrictive step-therapy protocols. For complex cancer treatment, the prior authorization burden and network restrictions on specialty oncology centers are material risks. See Medicare Advantage vs. Original Medicare for the full trade-off analysis.

Bone Density Monitoring and Bone-Modifying Agents

Long-term ADT causes bone loss that dramatically increases fracture risk. Medicare covers several protective interventions:

  • DEXA bone density scan: Covered every 24 months under Part B (more frequently if medically indicated with documented osteoporosis). Zero coinsurance for the scan itself.
  • Denosumab (Prolia): For ADT-induced osteoporosis, Prolia subcutaneous injections every 6 months are given in the physician’s office and billed as a Part B drug (20 percent coinsurance). See Medicare and Osteoporosis Coverage for details on denosumab vs. bisphosphonate coverage.
  • Zoledronic acid (Zometa): For bone metastases, IV zoledronic acid is a Part B infusion drug administered monthly.

Radiation for Bone Metastases

External beam palliative radiation to painful bone metastases is covered under Part B as outpatient radiation therapy. Single-fraction or short-course (5-fraction) regimens are increasingly preferred for palliation, reducing the total coinsurance burden compared to longer courses.

Medicare Advantage Considerations for Prostate Cancer

For men already enrolled in a Medicare Advantage plan when diagnosed with prostate cancer, several considerations are critical:

  1. Prior authorization for surgery and radiation: Both robotic prostatectomy and IMRT/SBRT typically require PA. Denials and appeals can delay treatment.
  2. Specialist access: Confirm that your urologist, radiation oncologist, and medical oncologist are all in-network. For high-volume robotic surgery programs or proton therapy centers, network exclusions are common.
  3. Oncology drug coverage: Advanced oral agents (enzalutamide, apalutamide) must be on the MA plan’s Part D formulary. Tier placement determines your copay.
  4. Switching to original Medicare: Men already enrolled in MA who are diagnosed with cancer may want to switch to original Medicare plus Medigap Plan G at the next Annual Enrollment Period (October 15–December 7) or a Special Enrollment Period. However, outside of SEPs, Medigap insurers in most states can medically underwrite new applicants—meaning a prostate cancer diagnosis may result in denial or premium surcharges outside the guaranteed-issue window.

Financial Assistance Programs

  • Medicare Extra Help: For Part D oral drugs (enzalutamide, abiraterone, etc.); see Medicare Savings Programs
  • Patient assistance programs: Pfizer (Xtandi), Johnson & Johnson (Zytiga/Erleada), Bayer (Nubeqa) all have manufacturer assistance programs for uninsured and underinsured patients, but these do not apply to Medicare beneficiaries in most cases
  • State pharmaceutical assistance programs (SPAPs): Some states provide supplemental prescription assistance to low-income Medicare beneficiaries beyond Extra Help
  • Cancer-specific nonprofits: CancerCare, Patient Advocate Foundation, and the Prostate Cancer Foundation all provide limited financial assistance grants

Planning Ahead

The most important financial planning step for any Medicare beneficiary newly diagnosed with prostate cancer is to evaluate coverage before treatment begins:

  1. Check Medigap eligibility: If you are within your guaranteed-issue window (first 6 months of Part B enrollment), enroll in Plan G immediately. If you are outside that window, apply now—even with a prostate cancer diagnosis, you may still qualify depending on the insurer and state.
  2. Understand Part D out-of-pocket maximum: The $2,000 cap (2026) makes oral hormonal agents far more affordable than in prior years.
  3. Ask about clinical trials: Medicare covers routine care costs for Medicare-covered clinical trials. See Medicare Cancer Treatment Coverage for the clinical trial benefit.
  4. Evaluate MA vs. original Medicare: If diagnosed while on MA, model what a switch to original Medicare + Plan G would save on your specific treatment plan. For patients receiving Radium-223, Sipuleucel-T, or Provenge, the savings can be enormous. See Medicare Supplement vs. Advantage Costs for a cost comparison framework.

Key Takeaways

  • PSA blood tests are covered under Part B at zero coinsurance; the annual DRE visit generates a copay.
  • Robotic prostatectomy is covered under Part B (outpatient) or Part A (inpatient) depending on the 2-midnight classification.
  • LHRH agonists (Lupron, Eligard, Zoladex) are Part B drugs billed in the physician’s office at 20 percent coinsurance.
  • Oral agents (enzalutamide, abiraterone, relugolix, apalutamide, darolutamide) are Part D drugs capped at $2,000/year out-of-pocket.
  • Infusion drugs for mCRPC (docetaxel, Radium-223, Sipuleucel-T) are Part B drugs with 20 percent coinsurance and no annual cap under original Medicare—making Medigap Plan G essential.
  • Medicare Advantage requires prior authorization for most prostate cancer treatments and may restrict access to high-volume surgical programs and specialty centers.